CN113784709B - 用于治疗炎症性病症的化合物和方法 - Google Patents

用于治疗炎症性病症的化合物和方法 Download PDF

Info

Publication number
CN113784709B
CN113784709B CN202080030668.4A CN202080030668A CN113784709B CN 113784709 B CN113784709 B CN 113784709B CN 202080030668 A CN202080030668 A CN 202080030668A CN 113784709 B CN113784709 B CN 113784709B
Authority
CN
China
Prior art keywords
doi
compounds
ibu
compound
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080030668.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN113784709A (zh
Inventor
C·D·尼克尔斯
G·比拉克
D·E·尼克尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Luis Anna State University Monitoring Committee College Of Agriculture And Mechanical Engineering
Original Assignee
Luis Anna State University Monitoring Committee College Of Agriculture And Mechanical Engineering
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luis Anna State University Monitoring Committee College Of Agriculture And Mechanical Engineering filed Critical Luis Anna State University Monitoring Committee College Of Agriculture And Mechanical Engineering
Priority to CN202410485765.2A priority Critical patent/CN118384143A/zh
Publication of CN113784709A publication Critical patent/CN113784709A/zh
Application granted granted Critical
Publication of CN113784709B publication Critical patent/CN113784709B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN202080030668.4A 2019-04-12 2020-04-13 用于治疗炎症性病症的化合物和方法 Active CN113784709B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410485765.2A CN118384143A (zh) 2019-04-12 2020-04-13 用于治疗炎症性病症的化合物和方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962833140P 2019-04-12 2019-04-12
US62/833,140 2019-04-12
PCT/US2020/027981 WO2020210823A1 (en) 2019-04-12 2020-04-13 Compounds and methods for treating inflammatory disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410485765.2A Division CN118384143A (zh) 2019-04-12 2020-04-13 用于治疗炎症性病症的化合物和方法

Publications (2)

Publication Number Publication Date
CN113784709A CN113784709A (zh) 2021-12-10
CN113784709B true CN113784709B (zh) 2024-05-10

Family

ID=72751451

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080030668.4A Active CN113784709B (zh) 2019-04-12 2020-04-13 用于治疗炎症性病症的化合物和方法
CN202410485765.2A Pending CN118384143A (zh) 2019-04-12 2020-04-13 用于治疗炎症性病症的化合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410485765.2A Pending CN118384143A (zh) 2019-04-12 2020-04-13 用于治疗炎症性病症的化合物和方法

Country Status (9)

Country Link
US (2) US12398093B2 (https=)
EP (2) EP3952851B1 (https=)
JP (1) JP7596296B2 (https=)
KR (1) KR20220008264A (https=)
CN (2) CN113784709B (https=)
AU (1) AU2020271915B2 (https=)
BR (1) BR112021020424A2 (https=)
CA (1) CA3136153A1 (https=)
WO (1) WO2020210823A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL309842A (en) * 2021-07-26 2024-02-01 Univ Louisiana State Compounds and methods for treating situations where the response depends on 5-HT2
SE2151519A1 (en) 2021-12-10 2023-06-11 Amidea Sweden Ab 2-(2,5-dimethoxyphenyl)ethanamine and uses thereof
WO2024010765A1 (en) * 2022-07-05 2024-01-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions for treating 5-ht2 conditions and methods of using the same
WO2024191924A2 (en) * 2023-03-10 2024-09-19 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007016190A2 (en) * 2005-07-28 2007-02-08 Duke University Antiparkinsonian action of phenylisopropylamines
US9642819B2 (en) * 2008-07-10 2017-05-09 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical Low dosage serotonin 5-HT2A receptor agonist to suppress inflammation
EP2884962B1 (en) * 2012-08-17 2019-05-01 Smartek International LLC Preparation of desiccated liposomes for use in compressible delivery systems
US20200078335A1 (en) * 2017-05-01 2020-03-12 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods to reduce pathogenesis
GB201715919D0 (en) 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
David E. Nichols等.1- (2,5-Dimethoxy-4(-t rifluoromethy1)phenyl-)2 -aminopropane: A Potent Serotonin 5-HT2A/2C Agonist.《Journal of Medicinal Chemistry》.1994,第37卷(第25期),第4346-4351页. *
Electron-Conformational Study for the Structure–Hallucinogenic Activity Relationships of Phenylalkylamines;Ahmet Altun等;《Bioorganic & Medicinal Chemistry》;第11卷;第3861–3868页 *

Also Published As

Publication number Publication date
US20220119340A1 (en) 2022-04-21
EP4685135A3 (en) 2026-04-15
EP4685135A2 (en) 2026-01-28
KR20220008264A (ko) 2022-01-20
BR112021020424A2 (pt) 2021-12-21
JP2022527401A (ja) 2022-06-01
WO2020210823A1 (en) 2020-10-15
JP7596296B2 (ja) 2024-12-09
EP3952851B1 (en) 2025-12-03
EP3952851A4 (en) 2023-01-11
CA3136153A1 (en) 2020-10-15
AU2020271915A1 (en) 2021-11-04
US12398093B2 (en) 2025-08-26
CN113784709A (zh) 2021-12-10
AU2020271915B2 (en) 2025-10-09
EP3952851A1 (en) 2022-02-16
US20260070872A1 (en) 2026-03-12
CN118384143A (zh) 2024-07-26

Similar Documents

Publication Publication Date Title
CN113784709B (zh) 用于治疗炎症性病症的化合物和方法
EP1807083B1 (en) Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
AU2009210655A1 (en) Treatment of bladder diseases with a TLR7 activator
KR20090129414A (ko) 인플루엔자 치료제
Xiang et al. Neotuberostemonine attenuates bleomycin-induced pulmonary fibrosis by suppressing the recruitment and activation of macrophages
JP2005512998A (ja) 抗マラリア治療剤に対する新規の使用
CN107438613B (zh) 用于预防或治疗感觉毛细胞死亡的化合物和方法
JP2025511217A (ja) メセンブリンの塩形態
JPH09507219A (ja) α−２−アドレノセプター作動剤として有用な７−（２−イミダゾリニルアミノ）キノリン化合物
JP2008526947A (ja) 抗マラリア活性を有する９ａ−カルバモイル−γ−アミノプロピル−および９ａ−チオカルバモイル−γ−アミノプロピル−アザリド
JP2008526948A (ja) 抗マラリア活性を有する９ａ−カルバモイルおよびチオカルバモイルアザライド
HK40056643A (en) Compounds and methods for treating inflammatory disorders
JP2001500526A (ja) 粘液溶解剤としての２−メチル−チアゾリジン−２，４−ジカルボン酸の使用
WO2022197885A1 (en) Compositions and methods for treating neurologic diseases
CN116672330A (zh) 一种盐酸达泊西汀复合物及其口溶膜
KR20080110760A (ko) 삼환성 트리아졸로벤즈아제핀 유도체를 포함하는 알레르기성 안질환 또는 알레르기성 비질환용 예방 또는 치료제
JPWO2004087148A1 (ja) 肺疾患の治療および／または予防剤
US20250270205A1 (en) Compositions and methods for inhibiting trem-1
WO2005011674A1 (ja) 気管支喘息の予防及び／または治療剤
WO2025160538A1 (en) Compositions and methods for treating hair graying and loss associated with aging
WO2024059853A2 (en) Haph analogs and therapeutic and diagnostic uses thereof
US20090087497A1 (en) Compositions and methods for treating symptoms of aging
JP2000302761A (ja) モルファン誘導体またはその塩
JPWO2005056009A1 (ja) 肺疾患治療剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40056643

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant